Citigroup
AKBA icon

Citigroup’s Akebia Therapeutics AKBA Stock Holding History

Citigroup’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-3,478
Closed -$22K – 7578
2019
Q4 		$22K Hold
3,478
– – ﹤0.01% 6884
2019
Q3 		$14K Sell
3,478
-1,147
-25% -$4.92K ﹤0.01% 6902
2019
Q2 		$22K Sell
4,625
-9,357
-67% -$53.2K ﹤0.01% 7033
2019
Q1 		$115K Buy
13,982
+2,845
+26% +$19.5K ﹤0.01% 5603
2018
Q4 		$62K Buy
+11,137
New +$87.2K ﹤0.01% 6050

Other funds holding AKBA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Citigroup's AKBA Position: Q2 2026 in Review

Citigroup reduced its Akebia Therapeutics (AKBA) stake by 61% in Q2 2026, selling an estimated $2.06M and leaving 1,124,570 shares worth $1.28M. The position accounts for ﹤0.01% of the portfolio, ranked #3269.

Citigroup first reported a position in AKBA in Q2 2014 and has held it in 49 quarters since. The position peaked at $8.26M in Q2 2020. 171 funds tracked by Wall St. Rank hold AKBA as of Q2 2026.

  • Citigroup held 1,124,570 shares of Akebia Therapeutics worth $1.28M as of Q2 2026.
  • Citigroup sold 1,730,016 Akebia Therapeutics shares in Q2 2026, an estimated $2.06M.
  • Akebia Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #3269 holding.
  • Citigroup first reported a position in Akebia Therapeutics in Q2 2014 and has held it in 49 quarters since.
  • Citigroup's Akebia Therapeutics position peaked at $8.26M in Q2 2020.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.